Ulcerative colitis screening

Ulcerative colitis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Ulcerative colitis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Abdominal X Ray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Alternative Treatments
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Ulcerative colitis screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Ulcerative colitis screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Ulcerative colitis screening
CDC on Ulcerative colitis screening
Ulcerative colitis screening in the news
Blogs on Ulcerative colitis screening
Directions to Hospitals Treating Ulcerative colitis
Risk calculators and risk factors for Ulcerative colitis screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2] Tarek Nafee, M.D. [3]

Overview

Patients with ulcerative colitis (UC) extending beyond the rectum have an increased risk of colitis-associated colorectal cancer (CRC), driven mainly by disease duration, extent, and cumulative inflammation, with the highest risk in patients with concomitant primary sclerosing cholangitis (PSC). Contemporary population-based data show a relative risk of approximately 1.4–1.7 compared with the general population, substantially lower than historical estimates but still above the threshold at which colonoscopic surveillance is recommended. All major societies recommend an index (baseline) colonoscopy approximately 8 years after symptom onset to re-stage disease extent and stratify risk, with immediate and annual surveillance for patients with PSC. Subsequent surveillance intervals (1, 3, or up to 5–10 years) are individualized according to inflammatory activity, extent, PSC, prior dysplasia, strictures, post-inflammatory polyps, and family history of CRC. Surveillance should be performed in remission, with high-definition colonoscopy, preferably with dye-based chromoendoscopy, by endoscopists trained in IBD surveillance. Random biopsies are now reserved for high-risk patients or for white-light-only examinations. Proctitis alone does not warrant IBD-specific surveillance.

Who Should Be Screened

Population	Recommendation
UC extending beyond the rectum (left-sided or extensive)	Index colonoscopy ~8 years after symptom onset to re-stage extent (with segmental biopsies) and assign a surveillance interval
UC with PSC (including after liver transplantation for PSC)	Colonoscopy at the time of PSC diagnosis, then annually
UC endoscopically confirmed as confined to the rectum	No IBD-specific surveillance; age-appropriate population CRC screening; reassess if symptoms suggest proximal extension
Childhood-onset UC	Consider surveillance at transition to adult care (age 16–18 years) at 1–3-year intervals
Age ≥75 years or significant comorbidity/frailty	Shared decision on continuing; discontinue when procedural risk exceeds expected benefit within life expectancy

• Disease extent should be defined by the maximal historical extent, including histologic extent; the index colonoscopy should include biopsies from each colonic segment to document histologic activity and extent.
• UC with concurrent Lynch syndrome or another hereditary CRC syndrome should follow the most intensive applicable surveillance program.

Risk Stratification and Surveillance Intervals

Risk Factors for Colitis-Associated Neoplasia

• Fixed: disease duration, extent (proximal to the splenic flexure), PSC, family history of CRC in a first-degree relative, young age at diagnosis, male sex, older age.
• Modifiable / dynamic: cumulative endoscopic and histologic inflammation (the key modifiable risk factor), colonic stricture, post-inflammatory polyps, prior dysplasia, and smoking (HR 1.17 per 10 pack-years for colorectal neoplasia).
• Risk factors should be reviewed at least annually in clinic and after every surveillance examination, and intervals adjusted accordingly.

Surveillance Intervals by Guideline

Guideline	Annual (high risk)	Intermediate interval	Longest interval (low risk)
BSG 2025 (GRADE methodology; good practice statements)	Moderate active inflammation after optimized therapy, dysplasia, PSC, colonic stricture, or calculated moderate 5-year advanced colorectal neoplasia (aCRN) risk	3 years: mild active inflammation, extensive colitis, post-inflammatory polyps, first-degree relative with CRC (any age, Lynch syndrome excluded), or small calculated risk	10-year colonoscopic reassessment plus population CRC screening if none of these factors, or calculated 5-year aCRN risk close to population risk (<3.6%)
ECCO (2017 consensus; 2023 malignancy guideline)	Extensive colitis with severe active inflammation; stricture or dysplasia in past 5 years; PSC; first-degree relative with CRC <50 years	2–3 years: extensive colitis with mild–moderate inflammation, post-inflammatory polyps, first-degree relative with CRC ≥50 years	5 years: none of the above
AGA 2021 (clinical practice update; best practice advice)	PSC, moderate–severe inflammation of any extent, first-degree relative with CRC <50 years, dense pseudopolyposis, invisible dysplasia or higher-risk visible dysplasia within past 5 years	Every 1–5 years, guided by cumulative risk factors and the quality of prior examinations	Up to 5 years for low-risk patients with quiescent disease and high-quality prior examinations
ACG (2019; updated 2025)	PSC	Every 1–3 years based on combined risk factors and findings on prior colonoscopy	—
NICE CG118 (2011; reviewed 2026)	Extensive colitis with moderate–severe active inflammation; stricture in past 5 years; dysplasia in past 5 years in patients declining surgery; PSC or liver transplant for PSC; first-degree relative with CRC <50 years	3 years: extensive colitis with mild active inflammation, post-inflammatory polyps, first-degree relative with CRC ≥50 years	5 years: extensive quiescent colitis or left-sided colitis

Multivariable Risk Calculators

• The BSG 2025 guideline endorses the use of a validated multivariable calculator that estimates 5- and 10-year aCRN risk from up to eight clinical factors as an alternative to the "single highest risk factor" approach (IBD dysplasia calculator). It is validated for ages 18–75 and up to 30 years of surveillance follow-up, and does not incorporate family history, which must be considered separately.
• Two consecutive good-quality colonoscopies without endoscopic or histologic inflammation predict a very low risk of future advanced neoplasia and should prompt reassessment of the need for continued intensive surveillance.

Performing the Surveillance Colonoscopy

Timing and Preparation

• Surveillance is ideally performed when the colitis is in remission, because active inflammation impairs dysplasia detection and its histologic interpretation.
• Low-volume (2 L) polyethylene glycol preparation is recommended over 4 L PEG in the BSG 2025 guideline: equivalent cleansing success (RR 0.98; moderate certainty) with greater willingness to repeat (high certainty). Sulfate- and picosulfate-based preparations appear comparably effective.
• Inadequate preparation (e.g., Boston Bowel Preparation Scale <6) is associated with IBD PCCRC (OR 5.9); a repeat examination within 3–6 months is suggested rather than the standard 1-year repeat used in non-IBD practice.

Endoscopic Modality

Modality	Guideline position
High-definition (HD) vs standard-definition (SD) white-light endoscopy	HD recommended over SD (SCENIC: strong recommendation, low-quality evidence; BSG 2025: recommended)
Dye-based chromoendoscopy (DCE; indigo carmine or methylene blue) with HD colonoscopy	Suggested over HD white light (SCENIC: conditional, low-quality evidence; BSG 2025: suggested, low certainty). With SD colonoscopy, DCE is recommended (SCENIC: strong, moderate-quality)
Virtual chromoendoscopy (NBI, i-SCAN, FICE)	SCENIC: NBI not suggested in place of HD-WLE or DCE (conditional). BSG 2025: no recommendation possible
Computer-aided detection (CADe)	Not recommended for IBD surveillance (BSG 2025 expert opinion)

Biopsy Strategy

• Targeted biopsy or resection of all visible lesions is the cornerstone of modern surveillance; most dysplasia in UC is now endoscopically visible.
• Segmental biopsies (from each colonic segment and the rectum) should be taken to document histologic activity and extent, which determine future intervals.
• Non-targeted (random) quadrantic biopsies every 10 cm:
  • Required when HD white light is used without dye or virtual chromoendoscopy (approximately 4 biopsies every 10 cm in previously inflamed segments; AGA best practice advice 8).
  • Should be considered even when dye spray is used in high-risk groups: PSC, dysplasia within the colitis segment in the past 5 years, before segmental colectomy, a retained rectum, and the rectal cuff of an ileal pouch (BSG 2025 expert opinion).
  • In a community-based dye-spray cohort, random biopsies detected dysplasia in only 1.2% of colonoscopies overall but in 12.8% of patients with prior neoplasia.

Lesion Description and Pathology Reporting

• Lesions should be described with the modified Paris classification: polypoid (≥2.5 mm tall), nonpolypoid (<2.5 mm), or invisible (dysplasia found on non-targeted biopsy). The terms "DALM," "adenoma-like mass," and "flat dysplasia" should be abandoned.
• Lesion reports should include site, morphology, size, whether borders are clearly delineated, ulceration, features of submucosal fibrosis or invasion, and surrounding inflammation.
• Any suspected dysplasia should be reviewed by a second (preferably GI) pathologist and discussed at an IBD multidisciplinary team (MDT) meeting. p53 immunohistochemistry can help distinguish dysplasia from reactive atypia. Non-conventional dysplasia subtypes (e.g., goblet cell–deficient, crypt cell, serrated) carry similar or higher risk than conventional dysplasia. Serrated epithelial change without dysplasia does not by itself shorten the surveillance interval.

Surveillance After Dysplasia Detection

Detailed management of dysplasia is addressed in the treatment microchapters; the points below determine subsequent screening intervals.

• Adenomas or serrated lesions arising outside any segment ever affected by colitis are managed according to sporadic post-polypectomy guidelines.
• After complete endoscopic removal of polypoid dysplasia, surveillance colonoscopy is recommended rather than colectomy (SCENIC: strong, very low-quality evidence). For nonpolypoid dysplasia, surveillance is suggested (conditional, very low-quality). The pooled CRC incidence after endoscopic resection of IBD dysplasia is ~0.2 per 100 person-years.
• BSG 2025 post-resection intervals (good practice statements):
  • Polypoid low-grade dysplasia (LGD) <2 cm resected en bloc: annual surveillance for 5 years.
  • High-grade dysplasia (HGD), or LGD with higher-risk features (polypoid ≥2 cm, nonpolypoid, multifocal, or piecemeal resection): repeat at 3–6 months, then annually for 5 years.
  • After 5 years without recurrence and without high-risk patient factors, de-escalation may be considered.
• Invisible dysplasia (confirmed by a GI pathologist) should prompt referral to an endoscopist with IBD expertise for repeat HD chromoendoscopy (SCENIC: conditional, very low-quality evidence).
• Colectomy should be discussed for endoscopically unresectable visible dysplasia, invisible or multifocal dysplasia with high progression risk, settings where surveillance is ineffective (severe pseudopolyposis, strictures), or coexisting risk factors such as PSC or uncontrolled inflammation.

Surveillance After Colectomy

• After limited resection (segmental, subtotal, or total colectomy with retained rectum) for dysplasia or cancer, surveillance is suggested at 3–6 months and then annually for 5 years.
• After restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA), surveillance of the pouch and rectal cuff is not routinely required for all patients, but should be offered to those with risk factors (e.g., prior dysplasia or CRC, PSC). Non-targeted biopsies of the rectal cuff are appropriate in this group.

Clinically Actionable Recommendations

• Schedule an index colonoscopy ~8 years after symptom onset for every patient with UC, regardless of the extent documented at diagnosis.
• Start annual colonoscopy at diagnosis of PSC and continue after liver transplantation.
• Assign the next interval using documented risk factors (inflammation grade, extent, PSC, stricture, post-inflammatory polyps, prior dysplasia, family history) or a validated multivariable calculator, and record the interval explicitly in the report.
• Perform surveillance in remission, with split-dose low-volume preparation, using an HD colonoscope, preferably with dye-based chromoendoscopy and targeted biopsies.
• Take segmental biopsies for histologic activity at every surveillance colonoscopy; add quadrantic random biopsies every 10 cm in PSC, recent dysplasia, retained rectum/pouch cuff, or when chromoendoscopy is not used.
• Repeat the examination within 3–6 months when bowel preparation is inadequate or active inflammation limits assessment.
• Refer all dysplasia within a colitis-affected segment for second pathologist review and IBD MDT discussion.
• Optimize control of inflammation; persistent inflammation shortens the surveillance interval and is the principal modifiable risk factor.
• Build recall systems (registries, automated reminders) to improve concordance; delayed surveillance is a leading cause of PCCRC.
• Patients with proctitis alone should follow general population CRC screening.

Important Updates Compared with Older Teaching

• Lower contemporary risk: relative risk ~1.4–1.7 in modern cohorts vs historical cumulative risks of up to 18% at 30 years.
• Uniform start at ~8 years: the older practice of delaying the first colonoscopy to 12–15 years for left-sided colitis has been abandoned; all patients beyond proctitis are re-staged at ~8 years.
• Visible dysplasia paradigm: most dysplasia is visible with HD and chromoendoscopy; random biopsies are no longer routine for every patient.
• Endoscopic resection over reflex colectomy: completely resected visible dysplasia, including selected nonpolypoid lesions, is managed with continued surveillance.
• Terminology: DALM, ALM, and "flat dysplasia" are replaced by polypoid, nonpolypoid, and invisible dysplasia.
• Risk-tailored intervals: BSG 2025 introduces a minimum 3-year interval for patients under active surveillance, 10-year reassessment for population-level risk, and multivariable risk calculators.
• Cumulative inflammation (endoscopic and histologic) is recognized as the dominant modifiable risk factor.
• Pathology: non-conventional dysplasia subtypes and mandatory double reporting are now emphasized.

Clinical Pearls

• The index colonoscopy is a staging examination: histologic extent often exceeds endoscopic extent and determines the surveillance category.
• Persistent histologic inflammation counts as a risk factor even when the mucosa looks endoscopically normal.
• PSC trumps everything: annual surveillance from diagnosis, including after liver transplantation, with random biopsies added to targeted sampling.
• Approximately 32–33 random biopsies are needed to exclude dysplasia with 80–90% confidence; this is why lesion detection with HD/chromoendoscopy has replaced random sampling as the primary strategy.
• A colonic stricture in longstanding UC must be considered malignant until proven otherwise.
• UC-associated CRC often arises in younger patients, is more often right-sided, and has a worse stage-adjusted prognosis than sporadic CRC.
• Finding an early, surgically curable cancer on surveillance is still a surveillance success; not all colitis-associated CRC is preventable.

Common Pitfalls

• Failing to start surveillance because the patient "only had left-sided colitis" at diagnosis without re-staging.
• Performing surveillance during a flare and accepting the examination as adequate.
• Accepting poor bowel preparation and deferring the repeat examination by a year or more.
• Using random biopsies instead of careful inspection of the mucosa, or omitting random biopsies in high-risk patients.
• Biopsying a resectable lesion extensively before referral, which can cause submucosal fibrosis and hinder en bloc resection.
• Labeling an adenoma within a colitis-affected segment as "sporadic" and applying sporadic polyp intervals.
• Not referring dysplasia for second pathologist review and MDT discussion.
• Losing patients to follow-up without a recall system; delayed surveillance is a leading cause of post-colonoscopy CRC.
• Offering IBD surveillance to patients with proctitis alone, or omitting general population screening for them.
• Relying on commercial CADe systems that were not trained on IBD mucosa.